Given that AXL is known to be upregulated on leukemic MDS and AML stem cells [5–7]AXL inhibition has been explored as a potential new targeted therapy for patients with myeloid malignancies in several clinical trials [4, 5, 8]. Here, AXL is linked to myeloid neoplasm.